API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.biospace.com/article/crinetics-bags-second-phase-iii-win-for-acromegaly-heads-for-nda-submission-/
https://www.globenewswire.com//news-release/2024/03/12/2845006/0/en/Crinetics-Announces-Positive-Topline-Results-from-Phase-2-Trial-of-Paltusotine-for-the-Treatment-of-Carcinoid-Syndrome.html
https://www.globenewswire.com//news-release/2023/12/18/2798132/0/en/Crinetics-Announces-Positive-Initial-Findings-from-Ongoing-Open-Label-Phase-2-Study-of-Paltusotine-for-the-Treatment-of-Carcinoid-Syndrome.html
https://crinetics.com/crinetics-paltusotine-achieved-primary-and-secondary-endpoints-in-phase-3-pathfndr-1-acromegaly-study/
https://www.globenewswire.com/news-release/2023/06/21/2691951/0/en/New-Data-Demonstrating-Stable-Biochemical-and-Symptom-Levels-with-Two-Years-of-Oral-Paltusotine-Administration-Presented-at-ENDO-2023.html
https://www.globenewswire.com/news-release/2022/10/13/2533805/0/en/Enrollment-Completed-in-Phase-3-PATHFNDR-1-Study-Evaluating-Oral-Paltusotine-for-the-Treatment-of-Acromegaly.html
https://www.globenewswire.com/news-release/2022/02/28/2392880/0/en/Crinetics-Pharmaceuticals-and-Sanwa-Kagaku-Kenkyusho-Enter-into-Exclusive-Licensing-Agreement-for-the-Development-and-Commercialization-of-Paltusotine-in-Japan.html